Universal Health International Group Holding Ltd. (2211) AI Stock Analysis

• Market Cap: HK$160.29M
• Dividend Yield: N/A
• Average Volume (3M): 554.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: -34.73%
• EPS Growth: -4642.86%
• Country: HK
• Employees: 1,198
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.24
• Shares Outstanding: 110,546,220
• 10 Day Avg. Volume: 803,972
• 30 Day Avg. Volume: 554,009
• PEG Ratio: <0.01
• Price to Book (P/B): 0.27
• Price to Sales (P/S): 0.12
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: HK$1.50 ▼(-10.18% Downside)

The stock's overall score is primarily influenced by its financial performance, which highlights significant challenges such as declining revenues and profitability. Technical analysis provides a positive outlook with strong momentum, offsetting some of the financial concerns. Valuation suggests the stock may be undervalued, but the lack of a dividend yield reduces its appeal. Earnings call and corporate events do not contribute to the score due to lack of data.

Positive Factors

Strategic Share Capital Increase

The increase in share capital enhances financial flexibility, supporting growth initiatives and potentially improving market positioning.

Partnerships with Manufacturers

Strategic partnerships allow access to a wide product range, bolstering competitive advantage and market reach in the healthcare sector.

Expansive Distribution Network

A strong distribution network enhances market penetration and customer reach, crucial for sustained growth in the healthcare industry.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market demand or competitive positioning, potentially impacting long-term growth prospects.

Negative Cash Flow

Negative cash flow reflects operational inefficiencies and limits the ability to reinvest in growth, affecting financial stability.

Weak Profit Margins

Weak profit margins suggest cost management issues, reducing profitability and potentially hindering investment in strategic initiatives.

Universal Health International Group Holding Ltd. Business Overview & Revenue Model

Company Description

Universal Health International Group Holding Limited, an investment holding company, engages in the distribution, wholesale, and retail of drugs, healthcare products, and other pharmaceutical products in the northeastern region of the People's Republic of China. Its product categories include Chinese patent medicines, chemical preparations, antibiotics and biochemical drugs, traditional Chinese medicine decoction pieces, biological products, protein assimilation preparations, peptide hormones, blood products, disinfection products, medical equipment, prepackaged foods, nutritional foods, health care products, stereotyped packaging cosmetics, and daily necessities, as well as family planning supplies, such as contraceptives and utensils; dairy products comprise infant formula milk powder; etc. The company also provides storage services. It serves pharmaceutical retailers, hospitals, clinics, and distributors. The company was formerly known as Jintian Pharmaceutical Group Limited and changed its name to Universal Health International Group Holding Limited in July 2015. Universal Health International Group Holding Limited was founded in 1998 and is headquartered in Shenyang, the People's Republic of China.

How the Company Makes Money

Universal Health International Group Holding Ltd. generates revenue through the sale of pharmaceutical and healthcare products. Its primary revenue streams include the wholesale distribution of medicines to healthcare institutions, retail sales through pharmacies and online platforms, and the provision of medical devices. The company benefits from strategic partnerships with pharmaceutical manufacturers, enabling it to offer a diverse range of products. Additionally, its expansive distribution network and focus on the growing Chinese healthcare market contribute significantly to its earnings.

Universal Health International Group Holding Ltd. Financial Statement Overview

Summary

Universal Health International Group Holding Ltd. is experiencing financial difficulties with declining revenues and profitability. Although there's a positive net income for 2024, operational and cash flow challenges persist, with weak margins and a negative operating cash flow.

Income Statement

The company has experienced declining revenue over the past few years, with a significant drop from 2019 to 2024. In 2024, the gross profit margin is approximately 16.52%, which is low, indicating cost management issues. Despite a positive net income for the first time in years, the net profit margin remains minimal at 0.38%. The EBIT and EBITDA margins are also very slim, highlighting operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively stable equity position, with a modest debt-to-equity ratio of 0.20 in 2024, suggesting reasonable leverage. However, the equity ratio has decreased over the years, standing at 50.90% in 2024. The return on equity in 2024 is low at 0.12%, indicating limited profitability from shareholders' equity.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating cash flow and free cash flow in 2024. The company has not shown substantial improvement in cash flow generation over the years. The operating cash flow to net income ratio is negative, reflecting poor cash conversion from profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	711.51M	711.51M	1.09B	1.30B	1.27B	1.19B
Gross Profit	113.39M	106.49M	179.88M	222.60M	215.32M	56.19M
EBITDA	-4.95M	-11.85M	12.59M	-70.62M	-160.78M	-560.83M
Net Income	-26.01M	-26.01M	413.00K	-105.40M	-187.65M	-675.40M
Balance Sheet
Total Assets	447.60M	447.60M	692.88M	797.10M	983.55M	1.15B
Cash, Cash Equivalents and Short-Term Investments	13.86M	13.40M	36.92M	89.37M	58.63M	33.09M
Total Debt	25.00M	25.00M	70.60M	40.62M	40.00M	3.93M
Total Liabilities	130.03M	130.03M	339.99M	457.57M	504.47M	459.02M
Stockholders Equity	317.57M	317.57M	352.72M	314.73M	408.13M	574.97M
Cash Flow
Free Cash Flow	8.69M	0.00	-101.75M	-19.47M	-47.94M	-126.92M
Operating Cash Flow	8.69M	0.00	-101.73M	-19.40M	-47.81M	-124.67M
Investing Cash Flow	7.12M	0.00	54.88M	-8.02M	11.09M	19.72M
Financing Cash Flow	-4.30M	0.00	40.23M	11.27M	55.96M	-10.21M

Universal Health International Group Holding Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2211, the sentiment is Negative. The current price of 1.67 is below the 20-day moving average (MA) of 1.75, below the 50-day MA of 1.81, and above the 200-day MA of 1.41, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 18.98 is Positive, neither overbought nor oversold. The STOCH value of 3.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2211.

Universal Health International Group Holding Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$380.45M	11.93	4.28%	7.10%	-2.88%	-22.83%
2211	59 Neutral	HK$160.29M	-4.15	-7.71%	―	-34.73%	-4642.86%
1110	56 Neutral	HK$315.38M	53.06	0.86%	5.87%	-10.78%	-82.81%
2197	52 Neutral	HK$3.76B	-3.61	―	―	79.98%	-3.40%
3390	52 Neutral	HK$263.73M	-9.19	-4.89%	28.00%	-1.68%	-111.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2393	44 Neutral	HK$279.56M	-1.59	-29.79%	―	6.10%	-115.12%

Universal Health International Group Holding Ltd. Corporate Events

Universal Health International Secures Unanimous Approval at AGM

Universal Health International Group Holding Ltd. held its Annual General Meeting on December 11, 2025, where all proposed resolutions were unanimously approved by shareholders. The resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to the board for share issuance and repurchase, reflecting strong shareholder support and stability in the company’s governance.

The most recent analyst rating on (HK:2211) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Universal Health International Group Holding Ltd. stock, see the HK:2211 Stock Forecast page.

Universal Health International Announces 2025 AGM and Key Resolutions

Universal Health International Group Holding Ltd. has announced its upcoming annual general meeting scheduled for December 11, 2025, in Shenyang City, China. The meeting will address several key resolutions, including the adoption of financial statements, re-election of directors, and re-appointment of auditors. Additionally, the company seeks approval for the directors to exercise powers to allot and issue shares, potentially impacting its capital structure and market operations.

The most recent analyst rating on (HK:2211) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Universal Health International Group Holding Ltd. stock, see the HK:2211 Stock Forecast page.

Universal Health International Proposes Modernization of Articles of Association

Universal Health International Group Holding Ltd. announced proposed amendments to its Articles of Association to align with updated Listing Rules and Cayman Islands laws. Key changes include enabling electronic communication, hybrid meetings, electronic payments, and the management of treasury shares. These amendments aim to modernize the company’s operations, improve shareholder engagement, and provide greater flexibility in capital management. The proposed changes are subject to shareholder approval at the upcoming annual general meeting.

The most recent analyst rating on (HK:2211) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Universal Health International Group Holding Ltd. stock, see the HK:2211 Stock Forecast page.

Universal Health International Reports Decline in Annual Financial Results

Universal Health International Group Holding Ltd. reported a significant decline in its financial performance for the year ended June 30, 2025, with revenue dropping by 34.7% to RMB 711.5 million and a net loss of RMB 25.7 million compared to a profit in the previous year. The company’s gross profit and operating profit margins also decreased, reflecting challenges in managing costs and market conditions. Despite these setbacks, the company managed a slight improvement in adjusted EBITDA, indicating some operational efficiencies.

The most recent analyst rating on (HK:2211) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Universal Health International Group Holding Ltd. stock, see the HK:2211 Stock Forecast page.